戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              VMAT seemed to be the optimal technique for NSCLC.
2                                              VMAT transport is inhibited by the competitive inhibitor
3                                              VMATs are also therapeutic drug targets for a number of
4                                              VMATs are targeted by an arsenal of therapeutic drugs an
5 rain, the vesicular monoamine transporter-2 (VMAT(2)) is responsible for the loading of dopamine (DA)
6 , DAT and vesicular monoamine transporter-2 (VMAT) in the striatum, medial forebrain bundle and the v
7 ng of the vesicular monoamine transporter-2 (VMAT-2) ligand dihydrotetrabenazine (DHTBZ) in a dose- a
8           Vesicular monoamine transporter-2 (VMAT-2) plays a critical role in dopamine storage by pac
9                         Because reserpine (a VMAT inhibitor) can precipitate depressive-like symptoms
10 omatic L-amino acid decarboxylase (AADC) and VMAT-2 genes.
11 ines must be actively transported by DAT and VMAT in tandem to produce psychostimulant effects.
12                                       HT and VMAT plans generated essentially equivalent PTV coverage
13 nt striatal neuronal loss, despite TH-IR and VMAT-IR reduction in a subset of animals, supporting the
14 fic differences in the expression of NET and VMAT-1 do not translate into differences in (123)I-MIBG
15                                    VAChT and VMAT exchange two protons per substrate molecule with ve
16                                    VAChT and VMAT exhibit partial structural and mechanistic homology
17        Comparative analysis of the VAChT and VMAT transport mechanisms will aid understanding of regu
18                  Harnessing proton antiport, VMATs enrich monoamines around 10,000-fold and sequester
19 s, HT was found to be superior to 2 or 8-arc VMAT for optimal OAR sparing (meeting all the dose const
20 onduct a study to compare HT and partial-arc VMAT in their ability to spare organs at risk (OARs) whe
21                                Halcyon based VMAT CSI plans are dosimetrically superior in terms of o
22             The MPD-induced increase in both VMAT-2 immunoreactivity and DHTBZ binding was attenuated
23              Interestingly, the Vmax of both VMATs for dopamine exceeded that for serotonin by 3-5-fo
24              This release was accompanied by VMAT-mediated serotonin depletion from the nucleus, a la
25 nction and results from net H(+) antiport by VMAT out of the vesicle lumen coupled to inward amphetam
26  consequence of the H(+) countertransport by VMAT that accompanies vesicular uptake, but not by induc
27            Hence, somatic vesicles loaded by VMAT during activity rapidly undergo exocytosis.
28 ms of the present study were to characterize VMAT representatives in rat gastric corpus, and to deter
29 res of MPP(+) and a previously characterized VMAT inhibitor, 3-amino-2-phenyl-propene, have been iden
30  monoamine transporter (VMAT), and a charged VMAT, substrate 1-methyl-4-phenylpyridinium (MPP(+)), re
31                  During the transport cycle, VMAT is expected to occupy at least three different conf
32 ition, MPD treatment increased and decreased VMAT-2 immunoreactivity in striatal vesicle subcellular
33 rodegeneration, whereas mutations decreasing VMAT and tyrosine hydroxylase exacerbated toxicity.
34                       We used the Drosophila VMAT (dVMAT) null mutant to globally ablate exocytotic a
35 ort characteristics and pharmacology of each VMAT isoform have been directly compared after expressio
36 , have been identified as the most effective VMAT inhibitors.
37 tant phenotypes can be rescued by C. elegans VMAT constructs and also (at least partially) by human V
38                               The C. elegans VMAT gene is cat-1; cat-1 knock-outs are totally deficie
39                                   C. elegans VMAT is associated with synaptic vesicles in approximate
40    The pharmacological profile of C. elegans VMAT is closer to mammalian VMAT2 than VMAT1.
41                              When C. elegans VMAT is expressed in mammalian cells, it has serotonin a
42 energy gradient for amine-proton exchangers (VMATs) to concentrate small transmitter molecules, for e
43 ; cat-1 knock-outs are totally deficient for VMAT immunostaining and for dopamine-mediated sensory be
44            Results of use of methodology for VMAT commissioning and quality assurance, utilizing both
45 ine receptor 1, dopamine transporters or for VMAT.
46 mors between 2018 and 2021, were planned for VMAT in True Beam (TB), and Halcyon (HAL) linear acceler
47 rection respectively with better results for VMAT (0.4%) vs. IMRT (1.6%) plans.
48 al elements, including the aminoethyl group (VMAT recognition), halogenated hydroxy-coumarin core (ra
49 embrane dopamine transporter (DAT) and human VMAT ortholog, VMAT2.
50                         Overall, we identify VMAT as an important regulator of sleep in Drosophila an
51                   Compared to TOMO and IMRT, VMAT achieved better target dose distribution and simila
52 such cases, increasing the number of arcs in VMAT cannot significantly improve OAR sparing.
53 gnificantly superior mean CI was observed in VMAT than in TOMO or IMRT (P = 0.013, 0.001).
54 ion of the aromatic ring gradually increases VMAT inhibition potency from 4'-F to 4'-I, parallel to t
55 of multiple metastases with single-isocenter VMAT.
56                                         Mean VMAT-1 expression in hereditary cluster 1 PPGLs was sign
57  results show that some CYAM is in DA neuron VMAT vesicles and suggests a new drug interaction in whi
58 ulated arc therapy [VMAT] vs non-IMRT or non-VMAT), cervical cancer stage at screening, and planned t
59 urther identified three cytosolic domains of VMAT(2) involved in the interaction with TH and AADC.
60 pine sensitivity, suggesting that effects of VMAT/reserpine on sleep are mediated by multiple monoami
61  and, because of its selective inhibition of VMAT-2, it preferentially depletes dopamine (DA).
62 ISC was strongly attenuated by inhibitors of VMAT (reserpine and tetrabenazine) and DAT (GBR12909 and
63  for DA in the MPD-induced redistribution of VMAT-2.
64 f substrate transport and drug inhibition of VMATs have remained elusive.
65 ggest possible differences in the sorting of VMATs versus VGLUTs to SVs at the synapse.
66 owever, did not correlate with either NET or VMAT-1 expression.
67 osely related VMAT(1) and with overexpressed VMAT(2).
68 -immunoprecipitates with the closely related VMAT(1) and with overexpressed VMAT(2).
69 amphetamine-induced deacidification requires VMAT function and results from net H(+) antiport by VMAT
70  of altanserin (5HTR2 inhibitor), reserpine (VMAT inhibitor), and VP16-XlCreb1 (constitutively active
71                                     To study VMAT's role in mediating amphetamine action in dopamine
72                             We conclude that VMAT expression confers the linked abilities to store bi
73                       There is evidence that VMAT activity modulates prohormone cleavage, but in the
74               Here, we provide evidence that VMAT(2) physically and functionally interacts with the e
75 -relevant target of reserpine, we found that VMAT-null mutants have an increased sleep phenotype, as
76                     Supporting the idea that VMAT is the sleep-relevant target of reserpine, we found
77                        However, although the VMAT mutants are consistently resistant to reserpine, ot
78  VMAT2; the latter was reduced to 5.8 by the VMAT inhibitor reserpine.
79  reversed the low-effort bias induced by the VMAT-2 inhibitor tetrabenazine, increasing selection of
80 in the presence of fragments involved in the VMAT(2)/TH/AADC interaction.
81 to define the structural requirements of the VMAT substrate and inhibitor activities.
82  modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibito
83 rimers to DNA sequences conserved within the VMAT family provided evidence for VMAT2, but not VMAT1 i
84                                VAChT and the VMATs contain COOH-terminal, cytoplasmic dileucine motif
85 zes to the same endosomal compartment as the VMATs by immunofluorescence, density gradient fractionat
86                              Conversely, the VMATs contain two glutamates upstream of their dileucine
87        In PC12 cells, VAChT differs from the VMATs by immunofluorescence and fractionates almost excl
88 mary, VAChT differs in localization from the VMATs in PC12 cells but not CHO cells.
89 Thus, VAChT differs in localization from the VMATs, which sort predominantly to LDCVs.
90 have investigated the phosphorylation of the VMATs.
91 nteract through distinct mechanisms with the VMATs and that the recognition of each ligand involves m
92 y (HT) and volumetric modulated arc therapy (VMAT) are both advanced techniques of delivering intensi
93 luates the volumetric modulated arc therapy (VMAT) dosimetric comparison between Halcyon ring gantry
94 -isocenter volumetric modulated arc therapy (VMAT) has been shown to decrease treatment time with the
95 py (TOMO), volumetric-modulated arc therapy (VMAT), and fixed-field intensity-modulated radiotherapy
96 ay include volumetric-modulated arc therapy (VMAT).
97  [IMRT] or volumetric-modulated arc therapy [VMAT] vs non-IMRT or non-VMAT), cervical cancer stage at
98 vesicular pH due to proton transport through VMATs.
99 th VHEE in treatment plans, in comparison to VMAT, indicating that VHEE can offer improved and safer
100 it is physically and functionally coupled to VMAT(2)-mediated transport into vesicles.
101                 HT appears to be superior to VMAT in OAR sparing mainly in cases which require confor
102 ffects of the vesicular monoamine transport (VMAT) inhibitor tetrabenazine.
103 ffects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine (TBZ) were investigated.
104 tion of the vesicular monoamine transporter (VMAT) blocks amphetamine-induced locomotion and self-adm
105 ment of the vesicular monoamine transporter (VMAT) for the vesicular storage and exocytotic release o
106 ging by the vesicular monoamine transporter (VMAT) is essential for mood-controlling serotonin transm
107 sion of the vesicular monoamine transporter (VMAT) rescued the dopamine toxicity and neurodegeneratio
108 that act as vesicular monoamine transporter (VMAT) substrates and ratiometric fluorescent pH sensors.
109 fin granule vesicular monoamine transporter (VMAT) that have been previously characterized as potent
110 itor of the vesicular monoamine transporter (VMAT) that repackages monoamines into presynaptic vesicl
111 (VAChT) and vesicular monoamine transporter (VMAT) transport neurotransmitter substrates into secreto
112             Vesicular monoamine transporter (VMAT), a member of the largest superfamily of transporte
113  acting via vesicular monoamine transporter (VMAT), and a charged VMAT, substrate 1-methyl-4-phenylpy
114 ERT and the vesicular monoamine transporter (VMAT), we have identified a role for ongoing 5-HT releas
115             Vesicular monoamine transporter (VMAT)-2 has a crucial role in the neurotransmission of b
116 DAT) or the vesicular monoamine transporter (VMAT).
117 tes for the vesicular monoamine transporter (VMAT).
118 ting of the vesicular monoamine transporter (VMAT).
119 vity of the vesicular monoamine transporter (VMAT)2.
120 r (NET) and vesicular monoamine transporter (VMAT-1) was evaluated immunohistochemically in paraffin-
121 ly related vesicular monoamine transporters (VMATs) 1 and 2 differ substantially in ligand recognitio
122        The vesicular monoamine transporters (VMATs) 1 and 2 show close sequence similarity but substa
123 esicles by vesicular monoamine transporters (VMATs) for controlled quantal release(6,7).
124 ies of the vesicular monoamine transporters (VMATs) indicate preferential localization to large dense
125 ly related vesicular monoamine transporters (VMATs) localize preferentially to large dense core vesic
126            Vesicular monoamine transporters (VMATs) pack monoamines into vesicles for synaptic releas
127        The vesicular monoamine transporters (VMATs) package monoamine neurotransmitters into secretor
128            Vesicular monoamine transporters (VMATs) translocate monoamines from the cytoplasm into se
129 tified two vesicular monoamine transporters (VMATs), one expressed in non-neural cells of the periphe
130  mammalian vesicular monoamine transporters (VMATs); it is 47% identical to human VMAT1 and 49% ident
131                             In larger tumor, VMAT provided the optimal dose distribution and sparing
132 iological rationale for the existence of two VMATs.
133 anism for differential regulation of the two VMATs.
134                  Agreement in the static vs. VMAT picket fence control point test was better than 0.5
135           Increasing the number of arcs with VMAT also led to some improvement in OAR sparing.
136  demonstrate that TH and AADC associate with VMAT(2)-containing synaptic vesicles from rat brain.
137 riata, TH and AADC co-immunoprecipitate with VMAT(2), whereas in PC 12 cells, TH co-immunoprecipitate
138 demonstrated that TH directly interacts with VMAT(2).
139 ncreasing from 2 to 8 arcs was observed with VMAT.

 
Page Top